相关临床试验
1424
95 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1787
已完成
1004
70.5%
Enrolling By Invitation
10
0.7%
尚未招募
28
2.0%
No Longer Available
2
0.1%
终止
105
7.4%
招募中
143
10.0%
暂停
4
0.3%
撤回
71
5.0%
进行中（未招募）
57
4.0%
暂无批准数据
- A University of Pittsburgh and Magee-Womens Research Institute study shows that inhibiting the NuRD complex, via MBD3/CHD4 knockdown or HDAC inhibitors, drives ovarian cancer cells into a reversible quiescent (G0) state. - Quiescent cells become dependent on proteasome and autophagy activity, so combining HDAC inhibitors with carfilzomib or chloroquine produces synergistic cell death, with synergy indices of 25–73 in vitro. - In an ovarian cancer PDX model, vorinostat plus carfilzomib markedly limited tumor growth, with tumors undetectable in two of nine mice, and valproic acid plus chloroquine induced mild tumor regression. - The authors plan a window-of-opportunity clinical trial combining HDAC inhibition with proteostasis inhibition in ovarian cancer, with valproic acid plus chloroquine as the most readily translatable repurposed-drug strategy.
- Women in socially vulnerable neighborhoods face a 20% higher risk of death after an ovarian cancer diagnosis compared to those in less vulnerable areas, according to a Pitt-led study published in JAMA Network Open. - Black women experience a 45% higher risk of death than white women, and the combination of Black race and high neighborhood vulnerability carries a greater risk than either factor alone. - The study analyzed data from 2,544 women (509 Black, 2,035 white) treated at the O'Neal Comprehensive Cancer Center at the University of Alabama at Birmingham, linking residential census tracts to the CDC's Social Vulnerability Index. - Researchers recommend health systems incorporate neighborhood-level measures into cancer care planning to identify at-risk patients and connect them with support services such as patient navigation and transportation assistance.
- Nearly 1 in 3 U.S. adults without heart disease have LDL cholesterol above the new 2026 ACC/AHA guideline goals, and about 76% of them are not receiving any cholesterol-lowering medication. - Among adults with established cardiovascular disease, nearly 4 in 5 are above the recommended LDL targets, with 38% receiving no treatment at all. - The 2026 guideline expands primary prevention statin eligibility to an additional 21.5 million Americans, bringing the total to 87.5 million (56.6% of adults aged 30–79). - Newly eligible populations are predominantly younger and lower risk, including nearly 20 million individuals with less than 3% estimated 10-year ASCVD risk.
- A randomized trial of 276 women found that point-of-care NAAT (Xpert Xpress MVP) raised appropriate treatment within 24 hours to 83.2%, versus 51.3% with usual care (P < 0.001). - Among women with no detectable vaginal pathogens, unnecessary antimicrobial treatment fell from 50.0% in usual care to 27.1% in the POC NAAT arm (P = 0.031). - Wet mount microscopy showed limited sensitivity (50% for Candida and TV, 63% for BV), while 87% of providers said they would adopt POC NAAT in routine practice. - The study, led by Magee-Womens Research Institute and the University of Pittsburgh, is the first randomized trial evaluating a multiplex molecular test for vaginitis at the point of care.
- A randomized trial of 400 participants aged 7–25 with Type 1 diabetes in Bangladesh and Tanzania found no significant difference between insulin glargine and human insulin in primary glucose outcomes at six months. - At 12 months, glargine was associated with less time in the very low glucose range and fewer nocturnal hypoglycemic events than usual care. - Glargine was also linked to lower total daily insulin use and fewer injections per day, factors relevant to patients, families, and health systems. - The findings inform global debate over whether resource-constrained health systems should prioritize newer, costlier insulin analogues over older human insulins.
- A preclinical study combining CAR T cell therapy with the radiopharmaceutical [67Cu]Cu-LLP2A produced greater tumor regression in neuroblastoma models than either treatment alone. - Adding CAR T cell therapy to radiopharmaceutical therapy increased tumor shrinkage and complete response rates by 80% in preclinical models. - The combination worked through two mechanisms: priming radiation-sensitive tumors for immune attack and remodeling radiation-resistant tumors to allow CAR T cell infiltration. - Researchers caution the findings are preclinical, with next steps including biomarker identification, imaging-guided dosing, and establishing safety and toxicity profiles before human studies.
- A four-week pilot trial at University of Pittsburgh found that cervical epidural spinal cord stimulation improved arm strength by 32% in seven chronic stroke survivors with profound motor deficits. - All seven participants experienced positive effects after less than nine hours of painless movement training, regardless of their initial mobility level. - The technology amplifies residual brain signals to the spinal cord rather than substituting them, representing what researchers call a "quantum change" in stroke rehabilitation. - Researchers estimate the technology could gain FDA approval for stroke patients within three to five years, with an extended clinical trial now recruiting.
- On April 12, 1955, Jonas Salk told Edward R. Murrow on live television that there was no patent on the polio vaccine, famously asking, "Could you patent the sun?" - The decision, which cost Salk an estimated $7 billion in forgone personal wealth, was made possible because the National Foundation for Infantile Paralysis (March of Dimes) had funded the research through millions of small public donations. - Because the formulation was freely shared, dozens of countries rapidly licensed production, and global wild poliovirus cases have fallen more than 99% since 1988, with only Afghanistan and Pakistan still reporting endemic transmission. - The 1954 field trial, involving 1.8 million American children, was the largest medical field trial in history and confirmed the vaccine was "safe, effective and potent" against all three polio strains.
- Acurex Biosciences received a grant from Aligning Science Across Parkinson's (ASAP) in partnership with The Michael J. Fox Foundation to advance its Parkinson's disease research program. - The multi-year collaboration, led by Professor Tim Greenamyre at the University of Pittsburgh, will investigate the role of the 15-lipoxygenase (15-LO) enzyme in Parkinson's disease progression. - Acurex's approach targets 15-LO with brain-penetrant small molecules to protect dopamine-producing neurons, aiming to develop disease-modifying treatments beyond symptom management. - The grant supports advancing lead drug candidates toward human clinical trials and joins the ASAP Collaborative Research Network, an international multidisciplinary effort.
- A one-year randomized clinical trial provides the first cause-and-effect evidence that 150 minutes of weekly aerobic exercise significantly reduces long-term cortisol levels. - The study, led by Dr. Peter J. Gianaros and Dr. Kirk I. Erickson, found a between-group difference in hair cortisol of –0.62 (95% CI: –1.14 to –0.10, p=0.039) favoring the exercise group. - Prior data from the same trial showed exercise also slowed the pace of brain aging, suggesting both chemical and structural brain benefits. - Researchers suggest meeting standard physical activity guidelines may be a simple behavioral strategy to build resilience against depression, anxiety, and heart disease.
